within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AD01_Papaverine;

model Papaverine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.166666666666667e-05,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0015,
    k12 = 1.3333333333333333e-05,
    k21 = 1.3333333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Papaverine</td></tr><tr><td>ATC code:</td><td>A03AD01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.3</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Papaverine is an opium alkaloid antispasmodic drug used to relax smooth muscles, primarily for the treatment of visceral spasms, vasospasm, and occasionally for erectile dysfunction by intra-arterial administration. It is not commonly used today due to the availability of safer and more effective alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous and oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Papaverine;
